Sonoma Pharmaceuticals (SNOA) Cut to “Hold” at Zacks Investment Research

Sonoma Pharmaceuticals (NASDAQ:SNOA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday.

According to Zacks, “Sonoma Pharmaceuticals operates as a pharmaceutical company. It develops and markets solutions for the treatment of dermatological conditions, animal health and advanced tissue care. The company operates primarily in United States, Latin America and Europe. Sonoma Pharmaceuticals formerly known as Oculus Innovative Sciences and is headquatered in Petaluma, California. “

Several other analysts have also commented on SNOA. Maxim Group raised their target price on Sonoma Pharmaceuticals from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Friday, November 10th. Benchmark started coverage on Sonoma Pharmaceuticals in a report on Thursday, December 28th. They set a “speculative buy” rating and a $10.00 target price on the stock.

Sonoma Pharmaceuticals (SNOA) traded up $0.12 during trading on Friday, reaching $5.56. The company had a trading volume of 18,085 shares, compared to its average volume of 35,275. The firm has a market capitalization of $24.61, a price-to-earnings ratio of -2.79 and a beta of 1.19. Sonoma Pharmaceuticals has a 12-month low of $4.16 and a 12-month high of $8.25. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.56 and a current ratio of 5.37.

ILLEGAL ACTIVITY WARNING: “Sonoma Pharmaceuticals (SNOA) Cut to “Hold” at Zacks Investment Research” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, formerly Oculus Innovative Sciences, Inc, is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid.

Get a free copy of the Zacks research report on Sonoma Pharmaceuticals (SNOA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply